

**** Materials for this course will release 10/20/2021****

Pediatric Pharmacy Specialty Recertification Literature Study: Module 2A-B (Cert # L219145)

Teaser: The Literature Study Module provides immediate access to peer-selected, contemporary articles that are relevant to specialty practice. After learners review the content, they must successfully complete an online assessment to earn recertification credit.

Tag: Certifications; Pediatrics



ACPE Numbers: Various – see listing below

Pre-Sale Date: 09/22/2021

Content Release Date: 10/20/2021

Expiration Dates: 04/19/2022

Activity Type: Application-based

CE Credits: 10 contact hours

Activity Fee: \$55 (ASHP member); \$110 (non-member)

Accreditation for Pharmacists



The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Target Audience

These Literature Studies are designed to help board-certified pharmacists who are seeking recertification contact hours to maintain their Board of Pharmacy Specialties (BPS).

Activity Overview

The Literature Study Module is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). This module consists of 2 online home study activities (see table below). Each activity is designed to assess the learners' ability to analyze and apply peer-selected contemporary articles to practice and includes a short video for enhanced learning and understanding.

Module 2A – Critical Care: This module focuses on updates in pediatric critical care issues including septic shock guideline, protocols for status asthmaticus, and dexmetomidine for prolonged sedation.

Module 2B – General Pediatrics: This module focuses on general pediatric topics including *S. aureus* bacteremia, guidelines for therapeutic monitoring of vancomycin in MRSA, comparison of acetaminophen and ibuprofen for fever and pain in infants, and safety and efficacy of AR101 for peanut allergy.

Learners will be required to review the content and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this Literature Study, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice.

These activities are part of the ASHP professional development program for BCPPS recertification approved by the BPS.

**** Materials for this course will release 10/20/2021****

Recertification Credit*

Board certified pharmacists are eligible to receive up to 10 contact hours of recertification credit for completing this module. To earn recertification credit, learners must review the activity content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.

Learning Activity	ACPE Number	Contact hours	*Assessment Pass Point
Pediatric Pharmacy Literature Study Module 2A: Critical Care	0204-0000-21-969-H01-P	5	76%
Pediatric Pharmacy Literature Study Module 2B: General Pediatrics	0204-0000-21-970-H01-P	5	84%

Articles and Learning Objectives

Module 2A: Critical Care

0204-0000-21-969-H01-P

This module focuses on updates in pediatric critical care issues including septic shock guideline, protocols for status asthmaticus, and dexmedetomidine for prolonged sedation.

Melendez E, Dwyer D, Donnelly D et al. Standardized Protocol is Associated with a Decrease in Continuous Albuterol Use and Length of Stay in Critical Status Asthmaticus. *Pediatr Crit Care Med*. 2020;21:451-60.

Learning Objectives:

- Describe the study by Melendez and colleagues of a quality improvement protocol for the management of critically ill children with severe status asthmaticus.
- Develop recommendations for the management of critically ill children with severe status asthmaticus.

Weiss SL, Peters MJ, Alhazzani W et al. Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children. *Pediatr Crit Care Med*. 2020 Feb;21(2):e52-e106.

Learning Objectives:

- Describe the Surviving Sepsis Campaign guidelines for managing septic shock and other sepsis-associated organ dysfunction in children.
- Develop recommendations for the management of septic shock and other sepsis-associated organ dysfunction in children.

Daverio M, Sperotto F, Zanetto L et al. Dexmedetomidine for Prolonged Sedation in the PICU: A Systematic Review and Meta-Analysis. *Pediatr Crit Care Med*. 2020;21(7):e467-e474.

Learning Objectives:

- Describe the systematic review and meta-analysis of dexmedetomidine for prolonged sedation in critically ill pediatric patients.
- Develop recommendations for the use of dexmedetomidine for prolonged sedation in critically ill pediatric patients.

**** Materials for this course will release 10/20/2021****

Module 2B: General Pediatrics

0204-0000-21-970-H01-P

This module focuses on general pediatric topics including *S. aureus* bacteremia, guidelines for therapeutic monitoring of vancomycin in MRSA, comparison of acetaminophen and ibuprofen for fever and pain in infants, and safety and efficacy of AR101 for peanut allergy.

McMullan BJ, Campbell AJ, Blyth CC et al. Clinical Management of Staphylococcus aureus Bacteremia in Neonates, Children, and Adolescents. *Pediatrics*. 2020;146(3).

Learning Objectives:

- Describe the clinical management of Staphylococcus aureus bacteremia (SAB) in neonates, children, and adolescents.
- Develop recommendations for the clinical management of Staphylococcus aureus bacteremia (SAB) in neonates, children, and adolescents.

Rybak MJ, Le J, Lodise TP et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. *Am J Health Syst Pharm*. 2020 May 19;77(11):835-864.

Learning Objectives:

- Describe the revised consensus guideline from the American Society of Health-System Pharmacists (ASHP), the Infectious Diseases Society of America (IDSA), the Pediatric Infectious Diseases Society (PIDS), and the Society of Infectious Diseases Pharmacists (SIDP) for therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus (MRSA) infections.
- Develop recommendations for dosing and therapeutic monitoring of vancomycin in pediatric patients with serious methicillin-resistant Staphylococcus aureus (MRSA) infections.

Tan E, Braithwaite I, McKinlay CJ, Dalziel SR. Comparison of Acetaminophen (Paracetamol) With Ibuprofen for Treatment of Fever or Pain in Children Younger Than 2 Years A Systematic Review and Meta-analysis. *JAMA Netw Open*. 2020;3(10):e2022398.

Learning Objectives:

- Describe the systematic review and meta-analysis comparing acetaminophen with ibuprofen for the short-term treatment of fever or pain in children less than 2 years of age.
- Develop recommendations for the short-term treatment of fever or pain in children less than 2 years of age.

Hourihane JO, Beyer K, Abbas A et al. Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial. *Lancet*. 2020;4:728-739.

Learning Objectives:

- Describe the AR101 Trial in Europe Measuring Oral Immunotherapy Success (ARTEMIS) in pediatric patients with a peanut allergy.
- Develop recommendations for the management of peanut allergies in pediatric patients.

**** Materials for this course will release 10/20/2021****

Faculty

Andrew Hatt, Pharm.D., BCPPS
Critical Care Pharmacist
Children's Hospital Colorado
Aurora, Colorado

Michelle Kussin, Pharm.D., BCOP
Co-director, Pediatric Antimicrobial Stewardship Program
Clinical Pharmacist, Pediatric Infectious Diseases
Riley Hospital for Children at Indiana University Health
Indianapolis, Indiana

Lisa Lubsch, Pharm.D., BCPPS, AE-C, FPPA
Clinical Professor
SIUE School of Pharmacy
Pediatric Pharmacy Specialist
Cardinal Glennon Children's Hospital
St. Louis, Missouri

Kathryn Merkel, Pharm.D., BCPS, BCPPS, BCIDP
Pharmacy Clinical Manager
St. David's South Austin Medical Center
Austin, Texas

Lane Nguyen, Pharm.D., BCPPS
Clinical Pharmacy Specialist
Memorial Sloan Kettering Cancer Center
New York, New York

Samie Sabet, Pharm.D., BCPPS, BCPS, AE-C
Assistant Professor of Pharmacotherapy
University of Oklahoma
Tulsa, Oklahoma

Content Matter Experts

Peter N. Johnson, Pharm.D., BCPPS, BCPS, FCCM, FPPAG
Professor of Pharmacy Practice
University of Oklahoma College of Pharmacy
Oklahoma City, Oklahoma

Jamie L. Miller, Pharm.D., BCPPS, BCPS, FPPAG
Associate Professor
University of Oklahoma College of Pharmacy
Oklahoma City, Oklahoma

Jennifer Thackray, Pharm.D., BCPPS, BCPS
Pediatric Oncology Clinical Pharmacy Specialist
Memorial Sloan Kettering Cancer Center
New York, New York

**** Materials for this course will release 10/20/2021****

Reviewers

Michelle C. Abalos, Pharm.D.
Susan R. Dombrowski, B.S.Pharm., M.S.

Field Testers

Lawrence Alejandro, Pharm.D. BCPPS
Deneshia Brodbeck, R.Ph., BCPPS
Jeff Butler, Pharm.D., BCPPS
Jasjinder Cheema, Pharm.D., BCPS, BCPPS
Debra Determan, Pharm.D., BCPPS
Darrin Dillingham, Pharm.D., BCPPS
Gina Gries, Pharm.D., BCPS, BCPPS
Aaron Harthan, Pharm.D., BCPPS
Sarrah Hein, Pharm.D., BCPPS
Amy Holmes, Pharm.D., BCPPS, FPPA

Melissa Johnson, Pharm.D., BCPPS
Emily Kurzen, Pharm.D., BCPPS
Lucas Orth, Pharm.D., BCPPS
Stephanie Pennington, Pharm.D., BCPPS
Patrick Rose, Pharm.D., BCPS, BCPPS
Anna Simmont, Pharm.D., BCPS, BCPPS
Tara Smith, Pharm.D., BCPPS
Shannon Song, Pharm.D., BCPPS
Carol Vollmer-Johnson, Pharm.D., BCPPS

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education's Standards for Commercial Support and the Accreditation Council for Pharmacy Education's Standards for Commercial Support, ASHP requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual or his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring in the last 12 months with a commercial interest whose products or services may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content.

All faculty and planners for ASHP education activities are qualified and selected by ASHP and required to disclose any relevant financial relationships with commercial interests. ASHP identifies and resolves conflicts of interest prior to an individual's participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

All other planners, presenters, reviewers, ASHP staff and others with an opportunity to control content report no financial relationships relevant to this activity.

Methods and CE Requirements

Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:

- Complete the attestation statement
- Review all content
- Complete and pass the assessments
- Complete the evaluations

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.

System Technical Requirements

Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating web sites. View the [minimum technical and system requirements](#) for learning activities.

Development: These activities were developed by ASHP.